The inability to conduct clinical trials and related disruptions remain the most important concern for majority of the companies across the globe.
GlobalData conducted a survey to identify primary business concerns related to coronavirus outbreak by company role.
Primary Business Concerns Related to the Covid-19 Outbreak by Company Role
An analysis of the survey finds that the concerns about clinical trial disruption were highest among contract research organisations (CROs), other contract service providers and Pharma/Biotech.
Around 26% of CROs said that clinical trial disruption is their primary concern, an opinion shared by 28% of pharma/biotech companies and 26% of other contract service providers. The same concern was expressed by 22% of clinical/investigator sites and 18% of government/academic institute.
The concerns for safety of patients recruited in trials were highest among clinical/ investigator sites at 28%, followed by pharma/biotech companies (20%), CROs (19%), government/academic institutes (18%) and other contract service providers (15%).
The clinical/Investigator sites were also found to be the most worried group for employee safety, with 28% of the respondents highlighting it as the primary business concern related to COVID-19 pandemic. The same concern was expressed by 21% of government/academic institutes, 19% of CROs, 14% of pharma/biotech companies and 12% of other contract service providers.
The concerns for CRO disruptions were highest among other contract service providers (14%), followed by CROs (13%), pharma/biotech companies (12%) and government/academic institutes (7%).
Approximately 13% of the other contract service providers noted that the impact on supply chains is their primary concern, followed by 12% of pharma/biotech companies, 11% of clinical/investigator sites, 11% of government/academic institutes and 10% of CROs.
Business development was noted as the primary concern by 14% of other contract service providers. It was followed by CROs (13%), government/academic institutes (11%), clinical/investigator sites (6%) and pharma/biotech companies (5%).
Around 14% of the government/academic institutes, which usually rely on grants to run clinical trials, noted that capital raising was their primary concern. The percentage declined to 7% among pharma/biotech companies, 6% among clinical/investigator sites, 4% among other contract service providers and to 1% among CROs.
The analysis is based on responses received to the Coronavirus Survey – COVID-19 and Decentralised Clinical Trials conducted by GlobalData between 04 June and 22 June 2020.